⌕
Avalo Therapeutics · AVTX · Nasdaq
Tenet 55 · Mixed
Compare
$6.76+0.15%At closeTenet 55 · Mixed
$6.76+0.01 (+0.15%)
At close: Nov 20, 2026, 4:00 PM ET· Nasdaq · USD

Avalo Therapeutics (AVTX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is AVTX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 20, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammat…

AVTX +0.1% todayRead at source ↗
● Zacks Investment ResearchNov 11, 2026 · 17:21 ET
Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks

Avalo Therapeutics (AVTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings e…

AVTX +0.1% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates

Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027 Advancing AVTX-010, a next-generation, long-acting anti-IL-1β antibody, toward …

AVTX +0.1% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammat…

AVTX +0.1% todayRead at source ↗
● Seeking AlphaOct 25, 2026 · 02:22 ET
Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

Avalo Therapeutics' positive LOTUS results now support a pivotal trial, and its monthly dosing gives it a potential differentiating factor in HS. Their balance sheet has enough runway to meet their upcoming milestones as…

AVTX +0.1% todayRead at source ↗
● BenzingaOct 23, 2026 · 08:44 ET
This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.…

AVTX +0.1% todayRead at source ↗
● Defense WorldOct 16, 2026 · 03:41 ET
Avalo Therapeutics (NASDAQ:AVTX) Hits New 52-Week Low – Time to Sell?

Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) hit a new 52-week low on Wednesday. The stock traded as low as $11.99 and last traded at $12.01, with a volume of 1,648,996 shares. The stock had previously close…

AVTX +0.1% todayRead at source ↗
● GlobeNewsWireSep 29, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflamma…

AVTX +0.1% todayRead at source ↗
● GlobeNewsWireSep 23, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflamma…

AVTX +0.1% todayRead at source ↗
● Defense WorldSep 20, 2026 · 05:09 ET
Christopher Ryan Sullivan Sells 12,394 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) CFO Christopher Sullivan sold 12,394 shares of Avalo Therapeutics stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price…

AVTX +0.1% todayRead at source ↗
● GlobeNewsWireSep 4, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflamma…

AVTX +0.1% todayRead at source ↗
● Seeking AlphaSep 4, 2026 · 10:19 ET
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise

Avalo Therapeutics (AVTX) is now a well-funded, registrational-stage biotech with validated Phase II data for abdakibart in hidradenitis suppurativa (HS). Abdakibart demonstrated statistically significant HiSCR75 respons…

AVTX +0.1% todayRead at source ↗
● GlobeNewsWireSep 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflamma…

AVTX +0.1% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

NVDA12−14.0%
ANT10−8.5%
AMD5−13.2%
LAW5+2.8%

Article counts from the last market-wide feed page, across every symbol we track and not just AVTX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.